- **Alkem Laboratories is a pharmaceutical company built on the simple idea of making high-quality medicines accessible - a mission it has pursued for over five decades since its founding in Mumbai in 1973. It started by challenging international players in the Indian market, built its first plant in Taloja in 1978, and later marked a defining moment when its anti-infective drug Taxim became India's first anti-infective drug to cross ₹1 billion in domestic sales. The recurring approach that explains the business is a relentless focus on operational leverage and cost discipline, using the cash flows from dominant positions in acute therapies to fund expansion into chronic diseases, biologics, and medical devices.** # Business segments A single pharmaceutical engine with three distinct go-to-market channels - branded generics sold to doctors and pharmacies across India, generic drugs shipped to the US, and a growing international business spanning over 40 countries - all fed by an in-house manufacturing and R&D backbone. ## 1. India branded generics: the foundation that funds everything else **A field force of over 13,500 medical representatives sells more than 800 brands directly to doctors, making Alkem the third most prescribed pharmaceutical company in India and the undisputed leader in anti-infectives for over 15 years.** - **Prescriptions drive revenue** - the company ranks #3 in prescriptions across all therapy areas, with its representatives visiting doctors who then prescribe Alkem brands that patients buy at pharmacies, creating a direct link between the field force and sales. - **Dominant in acute care** - it holds the #1 position in anti-infectives with a 13.2% market share, #2 in vitamins and minerals, and #3 in both gastrointestinal and pain therapies, giving it a top-4 seat in four of India's seven largest therapy areas. - **Mega-brands create staying power** - the PAN brand family is the second-largest in the Indian pharmaceutical market, and 20 brand families each generate over ₹1,000 million in sales, so the portfolio is not dependent on any single drug. - **Chronic therapies are the growth lever** - the company is deliberately shifting toward long-term conditions like diabetes, neurology, and dermatology, with chronic now contributing roughly 22% of the India business and growing faster than the acute portfolio. - **First-mover in new categories** - it launched semaglutide, a GLP-1 anti-obesity drug, on day one of patent expiry in March 2026 and rapidly captured an 11% unit market share, showing the speed at which its distribution engine can convert a new opportunity. ## 2. US generics: the second engine, built on filings and factory output **The company files Abbreviated New Drug Applications with the US FDA, gets them approved, and then manufactures and sells generic versions of established drugs - with about three-quarters of what it sells made in its own Indian factories.** - **A portfolio of mature molecules** - it has filed 192 ANDAs and received 167 approvals, focusing on diabetes, cardiovascular, iron deficiency, and pain management, where it holds the #1 market position in 8 of its top 20 molecules. - **Self-manufacturing controls quality and cost** - roughly 70-75% of US products are produced in-house at the Daman and Baddi facilities, so the company captures the manufacturing margin rather than paying a contractor. - **R&D spending is overwhelmingly US-focused** - approximately 90% of Alkem's research and development expenditure is directed at the US market, reflecting the regulatory and scientific intensity required to win ANDA approvals. - **Price erosion has stabilised** - the US generic market is known for relentless price competition, but erosion had settled to low single digits, making the business more predictable than in earlier years. ## 3. International markets: a portfolio of smaller bets across 40 countries **Beyond India and the US, Alkem sells generic formulations through subsidiaries and partners in markets from Chile to the Philippines, with over 1,100 products registered and a mix of branded sales and tender-based government contracts.** - **Registrations are the entry ticket** - the company has secured 224 product approvals in Chile, 144 in South Africa, 77 in Australia, and 37 in Europe, meaning it has already cleared the regulatory hurdles needed to sell in these markets. - **Tender business adds volume** - in Latin America and other regions, a portion of revenue comes from government tenders, which provide large but price-sensitive orders that complement the branded sales effort. - **Growth comes from therapy expansion** - the strategy is to take existing products into new therapy areas within each country and to in-license products from other companies where it makes sense, rather than building everything from scratch. # Manufacturing and quality: the shared production backbone **Eighteen factories - seventeen in India and one in the US - produce the formulations, active pharmaceutical ingredients, and biosimilars that feed all three go-to-market channels, with a regulatory record of over 25 US FDA inspections and no warning letters over 15 years.** - **Sikkim is the production heartland** - most domestic production happens at the company's Sikkim facilities, which benefit from tax incentives and have been audited and approved by regulators including the US FDA, the UK MHRA, and Australia's TGA. - **Backward integration into APIs** - the company makes its own active pharmaceutical ingredients at Mandva, Ankleshwar, and a facility in California, reducing dependence on Chinese imports for the key chemical inputs that go into its finished drugs. - **A greenfield plant is in the works** - in March 2026, Alkem secured 30 acres in Ujjain, Madhya Pradesh, to build a new formulations factory, with board-approved investment of up to ₹1,036 crores to be spent in phases, signalling capacity expansion ahead of demand. # Research and development: the pipeline engine **Over 500 scientists across three R&D centres work on everything from generic drug formulations to first-in-human clinical trials, with a deliberate pivot toward complex molecules and biosimilars that are harder for competitors to copy.** - **Bioequivalence is the core capability** - the Taloja clinical research facility is licensed to conduct the studies that prove a generic drug works the same as the original, and it has been inspected by regulators from the US, UK, Europe, Brazil, and Malaysia. - **Complex products raise the bar** - the company is developing 505(b)(2) products - drugs that are not entirely new but rely on modified delivery or new uses - with several programmes already in Phase I and Phase II clinical trials. - **Academic partnerships de-risk innovation** - collaborations with Harvard, Johns Hopkins, the NIH, and IIT Bombay give Alkem access to cutting-edge science without having to build every capability internally, including a licensed technology for colorectal cancer from Johns Hopkins. # Group structure and partners **Alkem Laboratories sits at the centre of a group of 29 subsidiaries, with the most strategically important being Enzene Biosciences (biologics), Alkem MedTech (medical devices), and Alkem Wellness (trade generics), each carved out to pursue a distinct opportunity with its own management focus and, in some cases, outside investors.** - **Enzene is the biologics bet** - Alkem holds 89% of this subsidiary, which has built a patented continuous manufacturing platform for biosimilars and launched seven products in India, including the world's first biosimilar of Cetuximab for head and neck cancer. - **Enzene also runs a CDMO** - the same factories that make Enzene's own biosimilars are being offered to global clients on a contract basis, with an order book already building and a target of ₹450-500 crores in sales at full capacity. - **MedTech is the newest leg** - the wholly owned subsidiary entered orthopaedic implants through a technology licence from US-based Exactech, acquired domestic manufacturer Bombay Ortho for backward integration, and in 2026 offered to buy Swiss cardiac device company Occlutech for cash to enter cardiovascular devices. - **Trade generics were separated for focus** - the low-cost, high-volume trade generics business was moved into a wholly owned subsidiary, Alkem Wellness, in October 2025, allowing the parent to concentrate on branded and export markets while the subsidiary chases underserved regions. - **US sales run through Ascend** - the American generics business operates through step-down subsidiary Ascend Laboratories LLC, which holds the ANDA filings and manages the customer relationships with wholesalers and pharmacies.